心脏骤停后入院时血浆脑啡肽原A 119-159与二肽基肽酶3有助于预测长期神经功能结局
这项多中心观察性研究纳入2016年瑞典4个ICU收治的190例成人心脏骤停存活者(院外136例、院内54例),于入ICU时采血检测penKid、bio-ADM和cDPP3,分析其与基于CPC量表的长期神经功能不良结局的关系。结果显示,不良结局与入院时penKid和cDPP3升高相关,与bio-ADM无关;校正ROSC时间、初始心律、入院GCS运动评分和瞳孔对光反射消失后,penKid的关联仍存在,cDPP3的关联不再存在。临床变量单独预测的AUC为0.90(95%CI 0.86-0.95),加入penKid后提高至0.93(95%CI 0.89-0.97,p<0.026);penKid和cDPP3单独预测的AUC分别为0.70和0.71。作者结论认为,入院时penKid和cDPP3可预测心脏骤停后长期神经功能结局,penKid加入临床变量后进一步改善预测效能。
要点
- 190例成人心脏骤停存活者入ICU时采血,不良长期神经功能结局与penKid和cDPP3升高相关,与bio-ADM无关。
- 校正ROSC时间、初始心律、入院GCS运动评分和瞳孔对光反射消失后,penKid的关联仍存在,cDPP3的关联不再存在。
- 临床心脏骤停变量单独预测长期神经功能不良结局的AUC为0.90(95%CI 0.86-0.95)。
- 临床变量加入penKid后AUC提高至0.93(95%CI 0.89-0.97,p<0.026)。
- penKid和cDPP3单独预测的AUC分别为0.70和0.71,属中等预测信息。
适用人群与场景
- 2016年瑞典4个ICU收治的成人心脏骤停存活者,共190例,其中院外心脏骤停136例、院内心脏骤停54例。
研究设计与关键结果
- 多中心观察性研究,纳入190例成人心脏骤停存活者,入ICU时采血并批量检测penKid、bio-ADM和cDPP3。
- 长期神经功能不良结局与入院时penKid和cDPP3升高相关,与bio-ADM无关。
- 校正ROSC时间、初始心律、入院GCS运动评分和瞳孔对光反射消失后,penKid的关联仍存在,cDPP3的关联不再存在。
- 临床心脏骤停变量单独预测的AUC为0.90(95%CI 0.86-0.95)。
- 临床变量加入penKid后AUC为0.93(95%CI 0.89-0.97,p<0.026)。
- penKid单独预测的AUC为0.70,cDPP3单独预测的AUC为0.71。
证据类型、等级与局限
- 多中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,心脏骤停后入院时血浆penKid和cDPP3可预测长期神经功能结局,penKid加入临床心脏骤停变量后进一步改善预测效能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: A large proportion of adult survivors of cardiac arrest have a poor neurological outcome. Guidelines recommend multimodal neuro-prognostication no earlier than 72-96 h after cardiac arrest. There is great interest in earlier prognostic markers, including very early markers at admission. The novel blood biomarkers proenkephalin A 119-159 (penKid), bioactive adrenomedullin (bio-ADM) and circulating dipeptidyl peptidase 3 (cDPP3) have not been previously investigated for the early prognosis of cardiac arrest survivors.
METHODS: This multicentre observational study included adult survivors of cardiac arrest admitted to intensive care at four Swedish intensive care units (ICUs) during 2016. Blood samples were collected at ICU admission and batch analysed. The association between admission plasma penKid, bio-ADM and cDPP3 and poor long-term neurological outcome, according to the Cerebral Performance Category (CPC) scale, was assessed by binary logistic regression. Their prognostic performance was assessed using the area under the receiver operating characteristic curve (AUC).
RESULTS: A total of 190 patients were included, of which 136 patients had suffered out-of-hospital and 54 patients in-hospital cardiac arrest. Poor long-term neurological outcome was associated with elevated admission plasma concentrations of penKid and cDPP3, but not with bio-ADM. The association for penKid, but not for cDPP3, remained after adjusting for clinical cardiac arrest variables with prognostic value (time to return of spontaneous circulation (ROSC), initial rhythm, admission Glasgow coma scale (GCS) motor score and absence of pupillary reflexes). The prognostic performance of above mentioned clinical cardiac arrest variables alone was very good with an AUC of 0.90 (95% confidence interval, CI, 0.86-0.95), but improved further with the addition of penKid resulting in an AUC of 0.93 (95% CI 0.89-0.97, p < 0.026). Plasma penKid and cDPP3 alone provided moderate long-term prognostic information with AUCs of 0.70 and 0.71, respectively.
CONCLUSION: After cardiac arrest, admission plasma levels of penKid and cDPP3, but not bio-ADM, predicted long-term neurological outcome. When added to clinical cardiac arrest variables, penKid further improved prognostic performance.
参考来源
- Thorgeirsdóttir B, Levin H, Spångfors M, et al. Plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 on admission after cardiac arrest help predict long-term neurological outcome. Resuscitation. 2021. PMID: 33930500. doi:10.1016/j.resuscitation.2021.04.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。